Escherichia coli Nissle 1917 as a Programmable Bridge Chassis for Biomanufacturing and Host-Responsive Living Systems
The breadth of the recent literature requires explicit positioning of the present review (Table 1). Recent reviews have described EcN as a therapeutic and industrial chassis [22], a microbial cell factory spanning genetic engineering and fermentation [23], and a model case for engineered-probiotic translation [24, 25]. Reviews of engineered-probiotic regulation and next-generation probiotics empha
Advanced Hub Main Navigation Menu
Early View e78440
REVIEW
Open Access
Escherichia coli Nissle 1917 as a Programmable Bridge Chassis for Biomanufacturing and Host-Responsive Living Systems
Xin-Yan Lu,
Xin-Yan Lu
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, People's Republic of China
Zhejiang Key Laboratory of Functional Structural Lipid Synthesis and Application, Hangzhou, People's Republic of China
National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Conceptualization, Writing - original draft, Visualization
Search for more papers by this author
Xin-Yue Fang
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, People's Republic of China
Zhejiang Key Laboratory of Functional Structural Lipid Synthesis and Application, Hangzhou, People's Republic of China
National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Writing - original draft, Visualization
Search for more papers by this author
Yu-Han Liu
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, People's Republic of China
Zhejiang Key Laboratory of Functional Structural Lipid Synthesis and Application, Hangzhou, People's Republic of China
National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Writing - original draft, Visualization
Search for more papers by this author
Jun-Yi Cao
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, People's Republic of China
Zhejiang Key Laboratory of Functional Structural Lipid Synthesis and Application, Hangzhou, People's Republic of China
National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Methodology, Investigation, Resources, Writing - original draft, Visualization
Search for more papers by this author
Xiao-Fan Ao
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, People's Republic of China
Zhejiang Key Laboratory of Functional Structural Lipid Synthesis and Application, Hangzhou, People's Republic of China
National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Writing - original draft, Visualization
Search for more papers by this author
Ling-Man Wang
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, People's Republic of China
Zhejiang Key Laboratory of Functional Structural Lipid Synthesis and Application, Hangzhou, People's Republic of China
National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Investigation, Resources
Search for more papers by this author
Mian Li
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Writing - review & editing
Search for more papers by this author
Corresponding Author
Xue Cai
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, People's Republic of China
Zhejiang Key Laboratory of Functional Structural Lipid Synthesis and Application, Hangzhou, People's Republic of China
National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Conceptualization, Writing - review & editing, Funding acquisition
Search for more papers by this author
Corresponding Author
Zhi-Qiang Liu
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, People's Republic of China
Zhejiang Key Laboratory of Functional Structural Lipid Synthesis and Application, Hangzhou, People's Republic of China
National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Funding acquisition, Project administration
Search for more papers by this author
Yu-Guo Zheng
Huadong Industry Technology Institute of Synthetic Biology, College of Biotechnology and Bioengineering, Zhejiang University of Technology, Hangzhou, People's Republic of China
State Key Laboratory of Green Chemical Synthesis and Conversion, Zhejiang University of Technology, Hangzhou, People's Republic of China
Zhejiang Key Laboratory of Functional Structural Lipid Synthesis and Application, Hangzhou, People's Republic of China
National and Local Joint Engineering Research Center for Biomanufacturing of Chiral Chemicals, Zhejiang University of Technology, Hangzhou, People's Republic of China
Contribution: Supervision
Search for more papers by this author
ABSTRACT
Microbial biomanufacturing and engineered probiotics increasingly use related microbial lineages across distinct product architectures, but the associated engineering and evidence requirements are rarely compared. Here, Escherichia coli Nissle 1917 (EcN) is evaluated as a programmable bridge chassis across four alternative deployment modes: purified molecule, cell-derived architecture/material, living-cell product, and host-state-responsive living system. The review links carbon–nitrogen–energy–redox allocation and global regulation to cellular-state trajectories, interface capacity, safety refactoring, materials-assisted protection, containment, and mode-specific qualification. Direct evidence includes 100-L heparosan fermentation, antibiotic-free β-alanine production, engineered outer-membrane-vesicle delivery, human studies of phenylalanine-consuming EcN, and glucose-responsive GLP-1 delivery in diabetic mice and non-human primates. The terminated SYNB1934 Phase 3 program is considered alongside positive studies to distinguish proof of function, pharmacodynamic activity, tolerability, manufacturing readiness, and late-stage efficacy. Operational criteria for bridge-chassis designation, explicit rules for boundary cases, and a prospective design–build–test–learn agenda are proposed. As functional embodiment changes, engineering priorities shift among flux, state, interface, formulation, containment, and evidence—not necessarily toward a more advanced mode.
1 Introduction: From Probiotic Strain to Programmable Chassis
Microbial engineering is increasingly asked to do more than maximize the concentration of a single product. Industrial cell factories must allocate resources efficiently, retain genetic function over long cultivations, tolerate heterogeneous process environments, and support economical recovery; living microbial systems must additionally sense context, interact with biological or material interfaces, remain controllable after administration, and satisfy a substantially higher safety burden. These requirements are usually treated in separate literatures—metabolic engineering for ex vivo production, synthetic biology for sense-and-respond systems, biomaterials for cell–material interfaces, and probiotic or live-biotherapeutic research for host deployment. A central challenge for the next generation of microbial technologies is therefore to connect these design spaces within a common chassis framework [1-3].
Escherichia coli Nissle 1917 (EcN) combines a long history of probiotic use with the genetic tractability of E. coli. Direct evidence now spans high-density heparosan fermentation [4-6], antibiotic-free pMUT-derived expression [7-9], precision genome editing [10-12], selected metabolite production [13-15], therapeutic secretion and extracellular-matrix formation [16-18], and material-protected or responsive systems [19-21]. This evidence permits comparison of design requirements across output forms, but it does not establish universal host superiority.
The breadth of the recent literature requires explicit positioning of the present review (Table 1). Recent reviews have described EcN as a therapeutic and industrial chassis [22], a microbial cell factory spanning genetic engineering and fermentation [23], and a model case for engineered-probiotic translation [24, 25]. Reviews of engineered-probiotic regulation and next-generation probiotics emphasize safety, persistence, and clinical development [26, 27]. Food and bioprocess reviews address resource-aware microbial production and precision-fermentation scale-up [28-30]. Combined physicochemical/genetic bacterial engineering and probiotic living materials have also been synthesized [2, 3]. An unresolved question is how chassis design changes when the functional output shifts from a purified molecule to a cell-derived structure, a living cell, and ultimately a host-state-responsive living system.
Recent review | Primary organizing axis | Shared subject matter | Primary integration issue not emphasized
---|---|---|---
Yu et al., 2023 [22] | EcN therapeutic and industrial chassis; tools and applications | EcN engineering toolbox; industrial and therapeutic uses | Functional embodiment and cross-scale control are not primary organizing axes.
Sadhu et al., 2025 [24] | Synthetic and metabolic engineering of gut microbiota with EcN as a case study | EcN translation and engineering trade-offs | Ex vivo manufacturing and mode-specific product qualification receive limited emphasis.
Hung et al., 2026 [23] | EcN microbial cell factory from genetic engineering to fermentation | Genome editing, metabolic rewiring, products, and fermentation | Deployment-dependent state, interface, and evidence requirements are not the principal organizing axis.
Chen et al., 2026 [25] | Programmable probiotics and translational challenges with EcN as a model chassis | Programmable probiotic framing and translation | Cross-scale comparison from molecular manufacture to living-system deployment is limited.
Di Pierro et al., 2026 [26] | Applications and regulation of engineered probiotics | Safety, horizontal gene transfer, containment, and regulation | Metabolic state and physical product embodiment are not integrated as primary design variables.
Kern et al., 2026 [27] | Next-generation and precision probiotics | Engineered strains, colonization, safety, and AI | Ex vivo manufacturing and interface/process engineering are outside the main scope.
Liu et al., 2025 [1] | Balancing cell growth and product synthesis | Growth–production trade-offs, dynamic control, and modeling | Stress fitness and interface function in probiotic-derived chassis are not central endpoints.
Lin et al., 2024 [2] | Physicochemical and genetic engineering of bacteria | Surface materials, genetic engineering, and combined systems | Cross-mode linkage to ex vivo manufacture and EcN cellular-state control is limited.
Sabio et al., 2026 [3] | Probiotic living materials | Engineered probiotics integrated with matrices | Molecular products and cell-derived architectures are not compared with living-material deployment.
Oh et al., 2026 [28] | Safe and resource-aware microbial design for food production | Burden, biosafety, downstream processing, and safe-by-design production | Product-form-dependent comparison across non-living and living EcN deployments is not the main focus.
Gao et al., 2025 [29]; Robertson et al., 2026 [30] | Precision-fermentation and bioprocess engineering | Scale-up, downstream processing, AI, and regulation | A probiotic-derived lineage spanning manufacturing and host-responsive deployment is not the organizing framework.
The literature is organized using a proposed programmable-bridge-chassis framework. “Bridge” denotes continuity within a traceable EcN lineage across ex vivo biomanufacturing, cell-derived architectures, viable-cell products, and host-state-responsive systems. It does not imply that EcN is universally superior to established production or probiotic hosts. The framework compares shared engineering modules, native assets and liabilities, and deployment-specific evidence requirements across modes.
A second premise is that native probiotic traits are not automatically engineering advantages. Colonization-associated structures, capsule synthesis, and metal acquisition can support persistence while imposing resource or safety costs [31-33]. Fimbrial and biofilm programs further shape surface behavior [34, 35]. At the regulatory level, RpoS- and ArcA-linked responses reallocate transcriptional capacity toward protection [36-38], whereas CRP/Cra and nitrogen-control systems couple nutrient availability to growth and metabolism [39, 40]. Rcs and H-NS add envelope and acquired-DNA control [41, 42]. Consequently, a probiotic chassis should be engineered by selective retention, removal, and control of native functions, not by treating the native background as a neutral container.
The framework is organized across four linked scales (Figure 1). At the molecular scale, metabolism and expression determine precursor, ATP, redox, ribosome, and membrane-protein demand. At the cellular scale, global regulation converts those demands and environmental signals into growth, production, protection, and interface phenotypes. At the interface scale, secretion, envelope engineering, extracellular matrices, coatings, and encapsulation determine interaction with a process, material, food matrix, tissue, or microbial community. At the system scale, the final product form determines manufacturing, safety, containment, regulatory, and evidence requirements. The four deployment modes are alternative product architectures rather than obligatory stages of technological progression; their dominant engineering problems differ because the final functional unit differs.
Food biomanufacturing is treated as one deployment branch within this broader framework. The central questions are when EcN-specific biology creates a measurable advantage, which native liabilities must be removed or constrained, and what evidence is sufficient for the intended product form. This framing avoids two unsupported extrapolations: that probiotic history establishes safety for a new engineered construct, or that a high titer in controlled culture establishes fitness in a complex product or host environment.
1.1 Review Scope and Evidence Classification
This article is a critical narrative review rather than a systematic review. Evidence was classified by provenance as (i) direct studies performed in EcN; (ii) mechanistic or engineering evidence transferred from other E. coli backgrounds; (iii) cross-chassis evidence used to examine generalizability; and (iv) clinical or trial-registry evidence. Negative, inconclusive, and terminated programs were retained when they informed design constraints or deployment qualification. No meta-analysis or pooled effect estimate was attempted because the products, endpoints, scales, and experimental contexts were not comparable.
Literature was identified through iterative searches of PubMed, Web of Science Core Collection, Scopus, Google Scholar, publisher databases, and ClinicalTrials.gov through 15 August 2026, using combinations of “Escherichia coli Nissle 1917,” “engineered probiotic,” “microbial cell factory,” “living therapeutic,” “outer-membrane vesicle,” “curli,” “material coating,” “precision fermentation,” and “clinical trial.” Peer-reviewed primary studies and reviews were used as the principal evidence base; trial registries were used to verify clinical status and reported outcomes. Duplicate reports from a single development program were treated as one trajectory while distinct preclinical, early clinical, and pivotal stages were retained when they answered different evidentiary questions. Quantitative values were checked against the corresponding primary study rather than inferred from secondary reviews.
Evidence depth was evaluated separately within each functional mode rather than on a universal scale. Mode I progressed from proof of function to controlled bioreactor, scale-relevant operation, and downstream or quality validation. Mode II progressed from architecture formation to compositional characterization, functional validation, and reproducible isolation or manufacture. Mode III progressed from preclinical studies to early clinical, Phase 2, pivotal testing, and approval. Mode IV progressed from in vitro circuit behavior to rodent, non-human-primate (NHP), and human validation. These ladders answer different questions and are not numerically interchangeable.
1.2 Operational Definition, Classification Rules, and Anchor Cases
For this review, a programmable bridge chassis is used as a provisional organizing concept for a traceable microbial lineage that meets four working criteria: direct evidence across at least two functional embodiments; shared or comparable engineering modules across those embodiments; native traits that create deployment-dependent assets or liabilities; and explicit mode-specific qualification endpoints. A collection of unrelated proof-of-concept studies without cross-mode comparability would not satisfy this working definition. These criteria organize the literature; they are not a validated regulatory standard or a ranking of chassis quality.
Deployment mode is assigned primarily by the final functional unit and by whether continued viability and state-responsive control are required. Isolated vesicles, bacterial ghosts, and extracellular matrices are classified as Mode II; viable cells whose principal function is stable activity without host-state-gated output are Mode III; systems in which an environmental or host signal actively gates growth, payload production, or release are Mode IV. Dual-mode labels are retained for boundary cases such as viable EcN producing OMVs or curli in situ. Anchor cases were selected because they provide direct EcN evidence at a distinct boundary—scale-relevant manufacture, a defined cell
原文出处:https://advanced.onlinelibrary.wiley.com/doi/full/10.1002/advs.78440
提示:本站仅汇集公开信息,版权归原作者与原发布媒体所有。
提示:本站仅汇集公开信息,版权归原作者与原发布媒体所有。